Scientific Advisory Board Endorses Influenza Drug Targets Identified in AI Drug Discovery Programme
Poolbeg Pharma PLC (AIM:POLB) Poolbeg Partners with a Nasdaq-Listed Biopharma
Poolbeg Pharma Partners with a Nasdaq-Listed Biopharma Company on its Oral Delivery Platform
Poolbeg Pharma PLC (AIM:POLB) Favourable Conclusion of Patent Opposition
Positive Conclusion Reached in Immunomodulator I Patent Opposition Patent opposition hearing cancelled
Poolbeg Pharma PLC (AIM:POLB) Immunomodulator I Patent Portfolio Strengthened
Notice of allowance for patent grant in Japan
Poolbeg Pharma PLC (AIM:PLOB) Immunomodulator I Patent Opposition Withdrawal
An important step in the continued protection of Poolbeg’s patent family
Poolbeg Pharma PLC (AIM:POLB) Interim results for the six months to 30 June 2023
Significant progress made and well positioned for future growth
Following the ‘greedflation’ controversy, Asda publishes fuel costs online
Asda has emerged as the pioneering supermarket to disclose its local fuel prices online, following indications from regulators that companies were amplifying their profit margins at the pump, a practice
Poolbeg Pharma PLC (AIM:POLB) AI led programme identifies influenza drug targets
Successful Artificial Intelligence led programme identifies multiple influenza drug targets
Poolbeg Pharma PLC (AIM:POLB) Oral Vaccine Programme Moves Forward
Next-Generation Oral Vaccine Programme Advancing Through Non-Dilutive Funding
Poolbeg Pharma PLC – Board Appointment
Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need, announces the appointment of Brendan Buckley as
Poolbeg Pharma PLC (AIM:POLB) Annual Report & AGM Notice
Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need, confirms that the Company’s
Poolbeg Pharma PLC (AIM:POLB) Results for the year ended 31 December 2022
Significant milestones reached, well capitalised and positioned for future growth